BAJAJ BROKING

Notification
No new Notification messages
One Mobikwik Systems IPO is Open!
Apply for the One Mobikwik Systems IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
glenmark pharmaceuticals stock

GLENMARK PHARMACEUTICALS Share Price

1526.4 -16.25 (-1.05%)
Dec 11 2024 03:30 PM Pharmaceuticals NSE: GLENMARK

GLENMARK PHARMACEUTICALS Share Price Update

As of the latest trading session, GLENMARK PHARMACEUTICALS share price is currently at 1526.4, which is down by -16.25 from its previous closing. Today, the stock has fluctuated between 1524.50 and 1549.90. Over the past year, GLENMARK PHARMACEUTICALS has achieved a return of 88.33 %. In the last month alone, the return has been -5.60 %. Read More...

GLENMARK PHARMACEUTICALS Performance

Day Range

Low1524.50 High1549.90
1526.40

52 Week Range

Low 771.00 High 1830.95
1526.40

GLENMARK PHARMACEUTICALS Share Price

7406

532296

GLENMARK

img img img img
No Data Available

Open Price

1542.65

Prev. Close

1542.65

Volume (Shares)

483855.00

Total traded value

7385.56

Upper Circuit

1696.90

Lower Circuit

1388.40

Note: The current prices & values are delayed, Login to your account for live updates.

GLENMARK PHARMACEUTICALS Fundamentals


(Standalone)

Market Cap (Cr) 43073.20
PE Ratio (TTM) 7.63
Book Value / Share 848.58
Beta 0.92
ROE 6.98%
EPS (TTM) 67.15
Dividend Yield 0.16%
Net Profit Qtr (Cr) 595.06

GLENMARK PHARMACEUTICALS Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 2594.89
Operating Expense 1924.12
Net Profit 595.06
Net Profit Margin (%) 22.93
Earnings Per Share (EPS) 21.09
EBITDA 861.70
Effective Tax Rate (%) 25.15
Particulars JUN 2024 (Values in Cr)
Revenue 2296.88
Operating Expense 1766.87
Net Profit 453.73
Net Profit Margin (%) 19.75
Earnings Per Share (EPS) 16.08
EBITDA 686.75
Effective Tax Rate (%) 26.61
Particulars MAR 2024 (Values in Cr)
Revenue 2077.13
Operating Expense 1786.57
Net Profit 4613.70
Net Profit Margin (%) 222.11
Earnings Per Share (EPS) 163.50
EBITDA 6430.64
Effective Tax Rate (%) 26.70
Particulars DEC 2023 (Values in Cr)
Revenue 1304.16
Operating Expense 1674.12
Net Profit -20.41
Net Profit Margin (%) -1.56
Earnings Per Share (EPS) -0.72
EBITDA 49.25
Effective Tax Rate (%) 72.96
Particulars SEP 2023 (Values in Cr)
Revenue 2170.40
Operating Expense 1897.96
Net Profit 302.35
Net Profit Margin (%) 13.93
Earnings Per Share (EPS) 10.72
EBITDA 497.41
Effective Tax Rate (%) 22.34
Particulars MAR 2024 (Values in Cr)
Revenue 7649.76
Operating Expense 7128.73
Net Profit 5167.29
Net Profit Margin (%) 67.54
Earnings Per Share (EPS) 183.13
EBITDA 7480.01
Effective Tax Rate (%) 26.18
Particulars MAR 2023 (Values in Cr)
Revenue 8019.67
Operating Expense 7138.86
Net Profit 1208.77
Net Profit Margin (%) 15.07
Earnings Per Share (EPS) 42.84
EBITDA 1962.84
Effective Tax Rate (%) 23.10
Particulars MAR 2022 (Values in Cr)
Revenue 8017.38
Operating Expense 6849.10
Net Profit 1997.79
Net Profit Margin (%) 24.91
Earnings Per Share (EPS) 70.80
EBITDA 2733.18
Effective Tax Rate (%) 14.53
Particulars MAR 2021 (Values in Cr)
Revenue 7450.91
Operating Expense 6094.30
Net Profit 1649.45
Net Profit Margin (%) 22.13
Earnings Per Share (EPS) 58.46
EBITDA 2360.48
Effective Tax Rate (%) 15.14
Particulars MAR 2020 (Values in Cr)
Revenue 6491.20
Operating Expense 5803.33
Net Profit 1354.55
Net Profit Margin (%) 20.86
Earnings Per Share (EPS) 48.00
EBITDA 1929.57
Effective Tax Rate (%) 11.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 278.11
ROE % -50.87
ROCE % 12.05
Total Debt to Total Equity 0.34
EBITDA Margin 17.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 335.75
ROE % 7.43
ROCE % 9.75
Total Debt to Total Equity 0.46
EBITDA Margin 16.56
Particulars MAR 2022 (Values in Cr)
Book Value / Share 322.03
ROE % 14.36
ROCE % 15.77
Total Debt to Total Equity 0.55
EBITDA Margin 20.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 250.37
ROE % 14.77
ROCE % 14.70
Total Debt to Total Equity 0.75
EBITDA Margin 19.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.14
ROE % 13.29
ROCE % 13.70
Total Debt to Total Equity 0.80
EBITDA Margin 17.77
Particulars MAR 2024 (Values in Cr)
Book Value / Share 814.01
ROE % 6.98
ROCE % 9.75
Total Debt to Total Equity 0.10
EBITDA Margin 30.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 633.57
ROE % 9.12
ROCE % 10.79
Total Debt to Total Equity 0.20
EBITDA Margin 29.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 593.21
ROE % 10.42
ROCE % 10.93
Total Debt to Total Equity 0.24
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 524.84
ROE % 11.77
ROCE % 12.39
Total Debt to Total Equity 0.26
EBITDA Margin 31.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 468.73
ROE % 10.76
ROCE % 11.13
Total Debt to Total Equity 0.27
EBITDA Margin 28.75
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1659.45
Total Assets 14358.62
Total Liabilities 14358.62
Total Equity 7847.54
Share Outstanding 282188156
Price to Book Ratio 1.18
Return on Assets (%) -10.45
Return on Capital (%) -16.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1160.29
Total Assets 19371.67
Total Liabilities 19371.67
Total Equity 9839.25
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 1.53
Return on Capital (%) 2.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1411.51
Total Assets 17083.28
Total Liabilities 17083.28
Total Equity 9438.12
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 5.51
Return on Capital (%) 7.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1139.15
Total Assets 15603.57
Total Liabilities 15603.57
Total Equity 7064.27
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 6.21
Return on Capital (%) 8.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1111.24
Total Assets 14684.80
Total Liabilities 14684.80
Total Equity 6070.11
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 5.28
Return on Capital (%) 7.35
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 129.15
Total Assets 27414.39
Total Liabilities 27414.39
Total Equity 22970.62
Share Outstanding 282188156
Price to Book Ratio 1.18
Return on Assets (%) 18.84
Return on Capital (%) 21.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 93.79
Total Assets 24585.92
Total Liabilities 24585.92
Total Equity 17877.46
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 4.91
Return on Capital (%) 5.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 29.63
Total Assets 22914.48
Total Liabilities 22914.48
Total Equity 16738.58
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 8.71
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 15.78
Total Assets 20617.52
Total Liabilities 20617.52
Total Equity 14809.50
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 8.00
Return on Capital (%) 8.95
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 88.25
Total Assets 18951.59
Total Liabilities 18951.59
Total Equity 13226.26
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 7.14
Return on Capital (%) 8.06
Particulars MAR 2024 (Values in Cr)
Net Income 569.18
Cash from Operations 782.04
Cash from Investing 4560.89
Cash from Financing -3906.12
Net change in Cash 389.32
Free Cash Flow 1680.42
Particulars MAR 2023 (Values in Cr)
Net Income 868.45
Cash from Operations 1265.93
Cash from Investing -528.49
Cash from Financing -77.45
Net change in Cash 19.44
Free Cash Flow 1873.69
Particulars MAR 2022 (Values in Cr)
Net Income 1441.24
Cash from Operations 1667.09
Cash from Investing -333.28
Cash from Financing -520.49
Net change in Cash 254.88
Free Cash Flow 2457.21
Particulars MAR 2021 (Values in Cr)
Net Income 1382.47
Cash from Operations 1641.45
Cash from Investing -675.23
Cash from Financing -441.77
Net change in Cash 14.19
Free Cash Flow 2416.21
Particulars MAR 2020 (Values in Cr)
Net Income 1096.07
Cash from Operations 1859.36
Cash from Investing -783.51
Cash from Financing -444.66
Net change in Cash 173.99
Free Cash Flow 2791.78
Particulars MAR 2024 (Values in Cr)
Net Income 7000.74
Cash from Operations 375.64
Cash from Investing 3197.19
Cash from Financing -2666.44
Net change in Cash 35.29
Free Cash Flow 570.76
Particulars MAR 2023 (Values in Cr)
Net Income 1571.87
Cash from Operations 1890.48
Cash from Investing -431.46
Cash from Financing -978.49
Net change in Cash 64.09
Free Cash Flow 2080.10
Particulars MAR 2022 (Values in Cr)
Net Income 2337.44
Cash from Operations 1606.78
Cash from Investing -896.92
Cash from Financing -305.12
Net change in Cash 14.02
Free Cash Flow 1770.13
Particulars MAR 2021 (Values in Cr)
Net Income 1943.75
Cash from Operations 1579.25
Cash from Investing -1235.23
Cash from Financing -80.79
Net change in Cash -72.60
Free Cash Flow 1790.72
Particulars MAR 2020 (Values in Cr)
Net Income 1534.64
Cash from Operations 1918.46
Cash from Investing -1607.38
Cash from Financing -139.41
Net change in Cash -167.68
Free Cash Flow 2037.66
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.90 37.87 3.59 505.01 37.54 / 77.70
BLISS GVS PHARMA LTD 155.50 19.46 1.62 1637.91 92.25 / 172.40
CIPLA LTD 1455.65 25.47 4.14 117560.12 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 414.95 144.08 4.20 1221.24 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.90 57.30 11.20 505.01 37.54 / 77.70
AMRUTAJAN HEALTH LTD 753.60 45.84 7.31 2178.71 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6634.15 128.84 24.41 16585.38 4050.15 / 8139.85
BLISS GVS PHARMA LTD 155.50 20.27 1.59 1637.91 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1537.10
  • 26 Days 1564.00
  • 10 Days 1532.90
  • 50 Days 1604.70
  • 12 Days 1525.50
  • 100 Days 1588.90
  • 20 Days 1547.20
  • 200 Days 953.50
1546.72
PIVOT
First Resistance 1572.43
Second Resistance 1602.22
Third Resistance 1627.93
First Support 1516.93
Second Support 1491.22
Third Support 1461.43
RSI 45.60
MACD -38.50
Commodity Channel Index (CCI) 41.45
ADX 46.63
Williams % R -26.97

Over 1 Month

down

-5.60

Over 3 Months

down

-10.71

Over 6 Months

down

27.90

Over 1 Year

down

88.33

Over 3 Years

down

43.15

Over 5 Years

down

36.04

GLENMARK PHARMACEUTICALS Future

Future: Price

26 Dec
1531.00
30 Jan
1542.00
25 May
0 100 200 300 400 500 600

Discount/Premium

26 Dec
4.60
30 Jan
15.60
25 May
0 1 2 3 4 5 6 7

Active Calls

1560.0
1959
1600.0
1687
1580.0
708
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1500.0
387
1400.0
328
1460.0
276
25 Jul
0 500 1000 1500 2000 2500

GLENMARK PHARMACEUTICALS Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
17.09
Promoter Holdings
46.64
FII
23.05
DII
13.2
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Saldanha Family Trust Shareholding of Promoter and Promoter Group 1.28241936E8 45.45
Hdfc Mutual Fund-hdfc Arbitrage Fund Public Shareholding 9662757.0 3.42
Government Pension Fund Global Public Shareholding 9181327.0 3.25
Smallcap World Fund, Inc Public Shareholding 8755888.0 3.1
Mirae Asset Elss Tax Saver Fund Public Shareholding 7896195.0 2.8
Ashish Dhawan Public Shareholding 7200000.0 2.55
Ellipsis Partners Llc Public Shareholding 3699943.0 1.31
Aditya Birla Sun Life Trustee Private Limited A/c Public Shareholding 3247446.0 1.15
Invesco India Midcap Fund Public Shareholding 3015552.0 1.07
Blanche Elizabeth Saldanha Shareholding of Promoter and Promoter Group 1114327.0 0.39
Glenn Mario Saldanha Shareholding of Promoter and Promoter Group 992939.0 0.35
Cherylann Maria Pinto Shareholding of Promoter and Promoter Group 758485.0 0.27
Robin Joseph Pinto Shareholding of Promoter and Promoter Group 497500.0 0.18
Neha Saldanha Shareholding of Promoter and Promoter Group 26000.0 0.01

GLENMARK PHARMACEUTICALS

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-09-18 2.5 Final 2023-09-19 Equity shares 2022-09-12 2.5 Final 2022-09-14 Equity shares 2021-09-08 2.5 Final 2021-09-10 Equity shares 2020-09-17 2.5 Final 2020-09-19 Equity shares 2019-09-19 2.0 Final 2019-09-21 Equity shares 2018-09-19 2.0 Final 2018-09-22 Equity shares 2017-09-20 2.0 Final 2017-09-22 Equity shares 2016-08-03 2.0 Final 2016-08-05 Equity shares 2015-09-10 2.0 Final 2015-09-14 Equity shares 2014-07-10 2.0 Final 2014-07-14 Equity shares 2013-07-18 2.0 Final 2013-07-22 Equity shares 2012-07-19 2.0 Final 2012-07-23 Equity shares 2011-07-28 0.4 Final 2011-08-01 Equity shares 2010-09-16 0.4 Final 2010-09-20 Equity shares 2009-09-10 0.4 Final 2009-09-14 Equity shares 2007-11-07 1.4 Interim 2007-11-08 Equity shares 2007-01-04 0.8 Interim 2007-01-05 Equity shares 2005-04-27 0.0 Interim 2005-05-02 Equity shares
Ex-Date Ex-Bonus Ratio
2005-03-08 2005-03-04 1:1
Ex-Date Old FV NEW FV Record Date
2007-09-10 2.0 1.0 2007-09-17 2003-10-23 10.0 2.0 2003-10-31

Glenmark Share Result Highlights

ParticularsSep 2024 (Values in Cr)Jun 2024 (Values in Cr)Mar 2024 (Values in Cr)Sep 2023 (Values in Cr)
Revenue₹2594.89₹2296.88₹7649.76₹2170.40
Operating Expense₹1924.12₹1766.87₹7128.73₹1897.96
Net Profit₹595.06₹453.73₹5167.29₹302.35
Net Profit Margin22.93%19.75%67.54%13.93%
Earnings Per Share₹21.09₹16.08₹183.13₹10.72
EBITDA₹861.70₹686.75₹7480.01₹497.41
Effective Tax Rate25.15%26.61%26.18%22.34%

Key Highlights:

  • Glenmark Pharmaceuticals has shown consistent growth in revenue and net profit, with a net profit margin of 22.93% for Q2 FY 2024.
  • The company reported an EBITDA of ₹861.70 Cr, indicating healthy operational performance.
  • Earnings Per Share (EPS) surged to ₹21.09 in Q2, demonstrating improved shareholder value.
  • The positive performance has contributed to the growth of the Glenmark Share Price, reflecting the company's solid financial health and potential for future returns.

Glenmark Share Annual Reports

ParticularsMar 2024 (Values in Cr)
Revenue₹7649.76
Operating Expense₹7128.73
Net Profit₹5167.29
Net Profit Margin67.54%
Earnings Per Share₹183.13
EBITDA₹7480.01
Effective Tax Rate26.18%

Key Highlights:

  • Despite challenges in Dec 2023, Glenmark Pharmaceuticals showed an impressive turnaround by FY 2024, with revenue increasing to ₹7649.76 Cr.
  • The company posted a net profit of ₹5167.29 Cr in Mar 2024, marking a net profit margin of 67.54%, a significant recovery from the loss in Dec 2023.
  • The Earnings Per Share (EPS) improved dramatically to ₹183.13 in FY 2024, demonstrating robust growth in profitability, which positively influenced the Glenmark Share Price.

Glenmark Share Dividend

Ex-DateDividend Amount (₹)Dividend TypeRecord DateInstrument Type
18 Sep, 20232.5Final19 Sep, 2023Equity shares

Key Highlights:

  • Consistent Payouts: Glenmark has issued both final and interim dividends over the years, demonstrating its financial strength and commitment to rewarding shareholders.
  • Recent Final Dividends: The company’s most recent final dividend of ₹2.5 per share was paid in 2023, following similar payouts in previous years.
  • Interim Dividends: Notably, Glenmark has also declared interim dividends, such as ₹1.4 in 2007 and ₹0.8 in 2007, showcasing its willingness to distribute earnings when appropriate during the year.
  • Shareholder Confidence: Both types of dividends illustrate the company's ongoing efforts to maintain investor confidence by sharing profits regularly, which positively impacts the Glenmark Share Price.

About GLENMARK PHARMACEUTICALS

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by GLENMARK PHARMACEUTICALS

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

The share price of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1526.4 and for BSE is ₹ 1526.1.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE is ₹ 4,30,73.20 Cr. and for BSE is ₹ 4,30,64.73 Cr. as of now.

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1830.95 and ₹ 771.00 and for BSE is ₹ 1830.05 and ₹ 766.65.

How to Buy Glenmark Pharmaceuticals Ltd share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Glenmark Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 88.33%.

What is the Current Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

Glenmark Pharmaceuticals Ltd share price is for NSE ₹ 1526.4 & for BSE ₹ 1526.1 as on Dec 11 2024 03:30 PM.

What is the Market Cap of Glenmark Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE ₹ 4,30,73.20 & for BSE ₹ 4,30,64.73 as on Dec 11 2024 03:30 PM.

What is the P/E Ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Dec 11 2024 03:30 PM the price-to-earnings (PE) ratio for Glenmark Pharmaceuticals Ltd share is 7.63.

What is the PB ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Dec 11 2024 03:30 PM, the price-to-book (PB) ratio for Glenmark Pharmaceuticals Ltd share is 848.58.

How to Buy Glenmark Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glenmark Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glenmark Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glenmark Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

1. Who is the CEO of Glenmark Pharmaceuticals Ltd?

The current CEO of Glenmark Pharmaceuticals Ltd is Glenn Saldanha, who is also the Chairman and Managing Director of the company. He has been a key figure in shaping the growth and success of Glenmark since its inception in 1977, leading its transformation into a global pharmaceutical player.

 

2. When was Glenmark Pharmaceuticals Ltd established?

Glenmark Pharmaceuticals Ltd was established on November 18, 1977. Since then, it has grown significantly, expanding its operations in various therapeutic areas and becoming a prominent player in the global pharmaceutical industry.

 

3. What factors influence the Glenmark Share Price?

Several factors influence the Glenmark share price, including the company's financial performance, new product launches, regulatory approvals, global market expansion, and developments in their R&D pipeline, particularly in the oncology, respiratory, and dermatology sectors. Market sentiment and broader economic conditions also play a critical role.

 

4. Is Glenmark Pharmaceuticals Ltd debt-free?

No, Glenmark Pharmaceuticals Ltd is not completely debt-free. As of March 2024, its consolidated debt stands at INR 9.9 billion, a reduction from higher amounts in previous years. The company is actively working towards prepaying most of its long-term debt using proceeds from the sale of its API business while maintaining a solid liquidity profile.

 

5. What is the CAGR of Glenmark Share?

The Compound Annual Growth Rate (CAGR) of Glenmark share price is as follows:

  • 10 Years: 7%
  • 5 Years: 37%
  • 3 Years: 46%
  • 1 Year: 95%

This reflects significant growth in recent years, particularly driven by strong performance in key therapeutic areas.

 

6. How has the Glenmark Share Price performed over the past year?

The Glenmark share price has surged by approximately 95.23% over the past year, with a 52-week high of ₹1,830.05 and a low of ₹764.25. While the stock has experienced slight declines in recent months—with returns of -10.65% over the past three months and -8.45% over the last month—the overall long-term outlook remains positive, with analysts giving it a "Buy" rating.

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader